A pre-clinical evaluation of an APRIL targeting antibody strategy in grouped ddY mice and non-human primates and correlation to pathogenic and immune related mechanisms
September 27, 2018 | International IgAN Symposium
A pre-clinical evaluation of an APRIL targeting antibody strategy in grouped ddY mice and non-human primates and correlation to pathogenic and immune related mechanisms
Safety, pharmacokinetics and pharmacodynamics of VIS649, a humanized monoclonal IgG2 targeting APRIL, for the treatment of IgAN in a GLP toxicology study in Cynomolgus Monkeys
September 27, 2018 | International IgAN Symposium
Safety, pharmacokinetics and pharmacodynamics of VIS649, a humanized monoclonal IgG2 targeting APRIL, for the treatment of IgAN in a GLP toxicology study in Cynomolgus Monkeys
Developments in Computational-Based Methods for Antibody Design
September 27, 2018 | Discovery on target
Developments in Computational-Based Methods for Antibody Design
Structure-Based Epitope Targeting for Engineering Functional Antibodies Against Nav1.7 for Pain
April 30, 2018 | PEGS
Structure-Based Epitope Targeting for Engineering Functional Antibodies Against Nav1.7 for Pain
Population Pharmacokinetic and Viral Dynamic Modeling of VIS410, aMonoclonal Antibody Against Influenza A Virus in a Human Challenge Model
February 23, 2018 | International Society for Influenza and Respiratory Viruses (ISIRV) Antiviral Drug Development Conference
Population Pharmacokinetic and Viral Dynamic Modeling of VIS410, aMonoclonal Antibody Against Influenza A Virus in a Human Challenge Model
VIS410, a Broad-Spectrum, Anti-Influenza A Monoclonal Antibody in Clinical Development Demonstrates Activity Against Recent Vaccine, Seasonal, and H7N9 Strains of Influenza
February 23, 2018 | International Society for Influenza and Respiratory Viruses (ISIRV) Antiviral Drug Development Conference
VIS410, a Broad-Spectrum, Anti-Influenza A Monoclonal Antibody in Clinical Development Demonstrates Activity Against Recent Vaccine, Seasonal, and H7N9 Strains of Influenza
Model-based Clinical Efficacy Prediction and Study Design Support for VIS410, a Novel Neutralizing mAb, in Combination with Oseltamivir, in Hospitalized Patients with Influenza A
February 23, 2018 | International Society for Influenza and Respiratory Viruses (ISIRV) Antiviral Drug Development Conference
